CD163 and ovarian cancer: A high CD163+/CD68+ ratio at diagnosis has been shown to be a stronger predictor of OS, than CD163+ alone [37] and Zhang et al. demonstrated that a high M1/M2 ratio was associated with extended survival in ovarian cancer, whereas neither subtype alone was prognostic [38].